Q1 2026 Kiniksa Pharmaceuticals International PLC Earnings Call Transcript
Key Points
- Kiniksa Pharmaceuticals International PLC (KNSA) reported strong revenue growth for ARCALYST, with sales reaching $214.3 million in the first quarter of 2026, a 56% increase year-over-year.
- The company raised its full-year 2026 revenue guidance to $930 million to $945 million, up from the previous guidance of $900 million to $920 million.
- Kiniksa's financial position remains robust, with a cash balance of $468.1 million and positive cash flow, enabling continued investment in growth opportunities.
- The company is advancing its clinical pipeline, with the KPL-387 Phase 2, Phase 3 study in recurrent pericarditis on track, and plans to start a Phase 1 study for KPL-1161 by the end of the year.
- Kiniksa has launched a targeted direct-to-consumer campaign, 'Hearts Home,' to increase awareness and adoption of ARCALYST among recurrent pericarditis patients, leveraging digital innovation and AI for cost-effective outreach.
- Despite the strong performance, Kiniksa faces industry-wide headwinds related to co-pay resets and changes in insurance plans, which could impact future revenue growth.
- The company's gross to net increased in Q1 compared to the prior quarter, although it was lower than Q1 of 2025, indicating potential fluctuations in financial metrics.
- There is a significant awareness gap, with only 14% of recurrent pericarditis patients being unaided aware of ARCALYST, which could limit market penetration.
- The transition to KPL-387 monotherapy involves complex clinical trials and regulatory processes, which could pose challenges in terms of time and resource allocation.
- Kiniksa's growth strategy relies heavily on the success of its clinical trials and commercialization efforts, which are subject to regulatory approvals and market dynamics.
Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals first-quarter 2026 earnings conference call. (Operator instruction). Please be advised, today's conference is being recorded. I would now like to hand the conference over to your speaker today, Jonathan Kirshenbaum, Investor Relations. Please go ahead.
Thank you, operator. Good morning, everyone, and thank you for joining Kiniksa call to discuss our first quarter 2026 financial results and recent portfolio execution. A press release highlighting these results can be found on our website under the Investors section.
As for the agenda, our Chief Executive Officer, Sanjiv k Patel, will start with an introduction. From there, Ross Moat, our Chief Operating Officer, will provide an update on ARCALYST commercial execution. Then, Kiniksa Chief Medical Officer, Dr. John Paolini, will review our KPL-387 development program and the ongoing Phase 2, Phase 3 clinical trial in recurrent
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
